{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:24:41Z","timestamp":1777440281417,"version":"3.51.4"},"reference-count":13,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:00:00Z","timestamp":1535155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K10150"],"award-info":[{"award-number":["16K10150"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K16055"],"award-info":[{"award-number":["18K16055"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Along with the expansion of therapeutic options for metastatic melanoma, the development of useful biomarkers is urgently required to predict and monitor treatment response. Serum 5\u2010<jats:italic>S<\/jats:italic>\u2010cysteinyldopa (5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>) has been identified as a diagnostic marker of malignant melanoma, but its utility as a biomarker for emerging therapeutic agents remains unknown. We assessed serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> in 12 metastatic melanoma patients (median age, 76\u00a0years; six men and six women) who had been treated with nivolumab (Nivo) at Shinshu University Hospital between 2014 and 2016. Serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> and lactate dehydrogenase levels before and at 3\u20136\u00a0weeks of Nivo treatment were obtained and their changes were compared with clinical responses as defined by the Response Evaluation Criteria in Solid Tumors criteria (version 1.1). A decrease of 10\u00a0nmol\/L or more of serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> was observed only in partial response patients (2\/3 cases, 67%), while an increase of 10\u00a0nmol\/L or more of serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> was witnessed only in progressive disease patients (4\/8 cases, 50%). Serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> changes were within \u00b110\u00a0nmol\/L in the remaining six patients (partial response, one; stable disease, one; progressive disease, four). The results of the four moderately affected progressive disease patients were suspected to have been influenced by small\u2010sized metastatic lesions, a mixed response that included diminished and enlarged metastatic lesions, prior therapy to Nivo with <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> inhibitors or radiation, or the development of brain metastasis. Serum 5\u2010<jats:italic>S<\/jats:italic>\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> in the early phase of Nivo treatment may be helpful to predict therapeutic response in metastatic melanoma.<\/jats:p>","DOI":"10.1111\/1346-8138.14605","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T07:38:29Z","timestamp":1535182709000},"page":"1340-1344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum 5\u2010<i>S<\/i>\u2010cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients"],"prefix":"10.1111","volume":"45","author":[{"given":"Toshikazu","family":"Omodaka","sequence":"first","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-2932","authenticated-orcid":false,"given":"Akane","family":"Minagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine Matsumoto Japan"},{"name":"Department of Dermatology Sapporo Medical University School of Medicine Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Wakamatsu","sequence":"additional","affiliation":[{"name":"Department of Chemistry Fujita Health University School of Health Sciences Toyoake Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-0960","authenticated-orcid":false,"given":"Tomonobu","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Cancer Therapy Shinshu University School of Medicine Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy Shinshu University School of Health Sciences Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-8037","authenticated-orcid":false,"given":"Hiroshi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine Matsumoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00487-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13651"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/clinchem\/40.3.495","article-title":"Improved HPLC determination of 5\u2010S\u2010cysteinyldopa in serum","volume":"40","author":"Wakamatsu K","year":"1994","journal-title":"Clin Chem"},{"key":"e_1_2_6_5_1","unstructured":"https:\/\/doi.org\/10.14921\/jscc1971b.19.2_184"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199106000-00009"},{"key":"e_1_2_6_7_1","first-page":"5073","article-title":"Prognostic value of serum 5\u2010S\u2010cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy","volume":"57","author":"Wimmer I","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.5227\/skincancer.30.174"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12677"},{"key":"e_1_2_6_11_1","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman S","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0127"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0852-6"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2748"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2F1346-8138.14605","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:56:27Z","timestamp":1694876187000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,25]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/1346-8138.14605"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14605","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,25]]},"assertion":[{"value":"2018-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}